NVT Logo (4).jpg
Novotech Acquires US-based Drug Development Consulting Firm, CBR International - Expands Drug Development and FDA Regulatory Expertise
09 janv. 2023 11h34 HE | Novotech
SINGAPORE, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Novotech, the leading Asia Pacific centered biotech CRO today announced the acquisition of CBR International, a global product development, clinical...
NVT Logo (4).jpg
Novotech Acquires European CRO – Strengthens Global Operations
09 janv. 2023 11h33 HE | Novotech
SINGAPORE, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Novotech announced today the acquisition of EastHORN, a European CRO with clinical, medical and regulatory expertise in multiple strategically important...
Phathom_Pharm_Logo_RGB.jpg
Phathom Pharmaceuticals Announces Positive Topline Results from Phase 3 PHALCON-NERD-301 Trial Evaluating Daily Dosing of Vonoprazan for Symptomatic Non-Erosive Gastroesophageal Reflux Disease (NERD)
08 janv. 2023 18h00 HE | Phathom Pharmaceuticals
Both vonoprazan 10 mg and 20 mg doses met the primary endpoint and showed highly statistically significant greater percentage of 24-hour heartburn free days as compared to placebo (p<0.0001)Data...
Virios Logo Blue.jpg
Virios Therapeutics Announces Scheduling of FDA Meeting in March 2023 to Discuss IMC-1 Fibromyalgia Phase 3 Program
05 janv. 2023 07h00 HE | Virios Therapeutics
ATLANTA, Jan. 05, 2023 (GLOBE NEWSWIRE) --  Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat...
PDS Biotech Logo.png
PDS Biotech Reports Median Overall Survival (OS) of 21 Months in Advanced, Refractory Cancer Patients Having Few Remaining Treatment Options and with Reported Historical Survival of 3-4 months
28 déc. 2022 08h00 HE | PDS Biotechnology Corporation
FLORHAM PARK, N.J., Dec. 28, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies...
Wave Logo with Swoosh_R.jpg
Wave Life Sciences Provides Positive Update on Proof-of-Concept Study for WVE-N531 in Duchenne Muscular Dystrophy
19 déc. 2022 07h37 HE | Wave Life Sciences USA, Inc.
53% mean exon skipping and <1% (BLQ) mean dystrophin expression six weeks after initiating biweekly multidosing PN chemistry improved pharmacology of WVE-N531 compared with Wave’s first-generation...
Graphic 1
Biosplice Announces Interim Data from Phase 3 Long-Term Extension Clinical Trial in Knee Osteoarthritis and the Initiation of a New Phase 3 Trial
15 déc. 2022 09h00 HE | Biosplice Therapeutics, Inc.
SAN DIEGO, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. (“Biosplice”), a clinical-stage biotechnology company pioneering first-in-class therapeutics based on small-molecule...
Parexel Master Logo_CMYK.png
Parexel Teams with MyEyeDr. to Increase Patient Access and Participation in Ophthalmology Clinical Trials
15 déc. 2022 09h00 HE | Parexel International LLC
BOSTON and DURHAM, N.C., Dec. 15, 2022 (GLOBE NEWSWIRE) -- Parexel, one of the world’s largest clinical research organizations (CROs) providing the full range of Phase I to IV clinical development...
PDS Biotech Logo.png
PDS Biotech Completes First Stage of Enrollment in Checkpoint Inhibitor Refractory Arm of Phase 2 Clinical Trial in Advanced HPV16 Positive Head and Neck Cancer
15 déc. 2022 08h00 HE | PDS Biotechnology Corporation
FLORHAM PARK, N.J., Dec. 15, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies...
Asia Pacific CRO of the Year 2022 for Best Practices in Clinical Trials
Data Shows 50% of New Trials Have Sites in Asia Pacific
14 déc. 2022 20h06 HE | Novotech
SINGAPORE, Dec. 14, 2022 (GLOBE NEWSWIRE) -- Novotech, the Asia Pacific centered biotech specialist CRO said the latest industry research publication by GlobalData and Novotech found almost 50% of...